Clinical trials

Three months of ginseng tablets taken twice a day lessened fatigue in people with neuromyelitis optica spectrum disorder (NMOSD), a placebo-controlled Phase 3 clinical trial found. Ginseng is a plant that has been used in traditional Chinese medicine for thousands of years. “This study revealed positive effects of ginseng…

Uplizna (inebilizumab) prevented disease attacks for people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether they had a genetic variant in the FCGR3A gene that’s associated with reduced efficacy of rituximab, a therapy commonly used off-label for NMOSD. That’s according to additional data analyses from the Phase…

Treatment with Uplizna (inebilizumab-cdon) effectively prevented disease attacks and disability worsening for Asian people with neuromyelitis optica spectrum disorder (NMOSD) in the Phase 2/3 N-MOmentum clinical trial, a new analysis found. “In the Asian [patient] subgroup, the risk of NMOSD attacks was reduced with [Uplizna] versus placebo ……

A Phase 2 clinical trial is testing InnoCare Pharma’s experimental oral medication orelabrutinib in people with neuromyelitis optica spectrum disorder (NMOSD). The trial (NCT05284175), being conducted at the Peking Union Medical College Hospital, in Beijing, China, was cleared by the country’s regulatory agency last year. InnoCare…

Committee-based assessments are reliable for identifying disease attacks in people with neuromyelitis optica spectrum disorder (NMOSD) in the N-MOmentum clinical trial, which tested the approved therapy Uplizna (inebilizumab-cdon), a new study shows. The study, “Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by…

The past few years have been challenging for me, my family, and especially my youngest daughter, Bella, who in 2017 was diagnosed at 9 years old with neuromyelitis optica spectrum disorder (NMOSD). At the time, the best course of therapy recommended by Bella’s neurologist was Rituxan…

SPHERES, a real-world registry for neuromyelitis optica spectrum disorder (NMOSD), is now collecting biological samples from consenting participants. Launched by CorEvitas and the Guthy-Jackson Charitable Foundation (GJCF) in 2021, the registry had been collecting long-term clinical data, but not biological samples. “The launch of this biospecimen…

Up to 4.6 years of treatment with Enspryng (satralizumab) continues to safely reduce relapse rates and prevent disability progression for people with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). That’s according to pooled data from the Phase 3 SAkuraSky (NCT02028884) and…

A global Phase 4 clinical trial of Enspryng (satralizumab), approved to treat the most common form of neuromyelitis optica spectrum disorder (NMOSD), is enrolling newly diagnosed and other patients who could not or did not take part in Phase 3 trials of the therapy. In addition to people new…

Uplizna (inebilizumab) reduces the formation of asymptomatic lesions in the nerves that connect the eyes to the brain in people with neuromyelitis optica spectrum disorder (NMOSD), according to a new data analysis from the Phase 2/3 N-MOmentum trial. Asymptomatic, or subclinical, lesions are those that don’t lead to…